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Introduction 
We have been asked to write a counter-view to appear alongside an interesting editorial discussing 
pragmatic trials, particularly in the setting of perioperative care, written by three well respected 
leaders in our field. We agree that there are common problems with the way randomised trials have 
been undertaken in the past, especially in anaesthesia and surgery. We also recognise that these 
problems undermine the value of research as a tool to improve patient care. We propose an 
alternative view of pragmatic randomised controlled trials in perioperative care and how future 
research might be improved. 
 
Why should we perform large randomised trials? 
Joshi, Alexander and Kehlet highlight the important role that evidence based medicine (EBM) plays in 
delivering high-quality patient care. While we agree with this view, many clinicians do not.[1] We have 
known for some time that systematic reviews and meta-analyses may produce discordant results 
which may in turn be at variance with the findings of large pragmatic RCTs.[2-4]  Consequently, the 
evidence on which we base our clinical practice must range from individual experience, to expert 
recommendations, and various forms of clinical research. Whilst clinical experience will always form 
the foundation of EBM, high-quality randomised trials have been placed at the apex of the evidence 
pyramid. This is not because they are perfect, but because in many cases they offer the best 
knowledge we have. Nevertheless, ardent proponents of EBM should acknowledge that many clinical 
questions simply cannot be answered with a randomised trial, either because this would be technically 
difficult, or because we lack the equipoise to randomise patients to what we believe may be sub-
standard care. The refusal of some leading authorities on EBM to acknowledge this point does nothing 
to help our patients. Meanwhile the frailty of the concept of clinician as infallible expert is widely 
reported in the mainstream media.[5] Airway management provides a good example of an area of 
practice where collective clinical experience has evolved an approach to patient care that is effective 
and safe, in the absence of large clinical trials.[6]  Anaesthesia and surgery are craft specialties and 
naturally weighted towards decisions informed by clinical experience and the trial of n=1. However, 
to assume that all clinical questions can be resolved in this way is a dangerous mistake.  
 
The tension between the craft of anaesthesia and the need for evidence is not new. John Snow is held 
in high esteem by both the anaesthetic and public health communities for his technical expertise in 
developing the craft of anaesthesia, and also his ability to apply epidemiological evidence to inform 
practice.[7] We encounter many simple questions in our daily practice that can only be answered at a 
population level. The relative merits of different anaesthetic, analgesic, or muscle relaxant drugs offer 
important examples.[8] It is tempting to believe an astute clinician can identify the risks and benefits 
of these treatments without reference to clinical research, but this view is dangerously unrealistic. 
Mainstream media is littered with examples of what happens to doctors whose clinical judgement 
fails them and, consequently, their patients. [9-11] Quality Initiatives such as ‘Getting it right first time’ 
have exposed widespread variations in perioperative practice which cannot be justified in terms of 
patient outcomes or healthcare costs.[12] The intensive care field has recently been enlivened by 
debate about a retrospective cohort study from a single US medical centre reporting dramatic effects 
of a cocktail of intra venous vitamin C, hydrocortisone and thiamine on survival amongst patients with 
sepsis.[13] The lead author has argued that it would be unethical confirm these findings in a 
randomised trial before starting treatment on septic patients. [14]  Society may initially support these 
exponents of seemingly miraculous treatments, but is no longer prepared to forgive when theories 
are found to be flawed. We argue that a well-designed and well implemented randomised trial 
provides the security of knowledge with a low risk of bias, and therefore offers the greatest benefit to 
our patients. 
 
When should we perform randomised trials? 
The decision to offer surgery to a patient must involve consideration of the potential benefit, as well 
as likely harms. There is growing recognition that we have more work to do in generating high-quality 
evidence to minimise the harm associated with anaesthesia and surgery, to inform patients and 
clinicians of risk, and hence maximise the overall benefit. The purpose of pragmatic (or clinical 
effectiveness) trials is to confirm the benefits of a treatment which has shown promise in smaller 
explanatory (or efficacy) trials whilst accounting for the practicalities of use in the real world clinical 
environment. Explanatory trials are designed to answer the question ‘Can this treatment work?’; 
they tend to be small in sample size, with tightly defined inclusion and exclusion criteria, ensuring 
ideal conditions for the study treatment to work. Pragmatic trials answer the question ‘Does this 
treatment work?’ and typically include widely generalisable populations in a large number of 
hospitals. Pragmatic trials are designed to embrace the variation between patients, doctors and 
hospitals because this represents the ‘usual care’ context in which we expect the treatment to work 
if implemented into routine practice. In reality, this is a continuum, and some trials are more 
pragmatic than others.[15,16]  Perhaps inevitably, the apparent benefits of new treatments are often 
diluted in pragmatic trials, when factors such as compliance, concomitant therapy and side-effects 
feature more prominently and diminish the effectiveness of study treatments. If this phenomenon is 
a reality for our patients, it must be reflected in our assessment of how well a treatment works. 
 
To us it seems obvious that it is important to know when a treatment is not effective in the normal 
clinical environment. However, some commentators debate the value of large trials which frequently 
fail to confirm the clinical effectiveness of treatments. The suggestion seems to be that we should 
somehow only study treatments which will be shown to work, or perhaps not study any treatments 
at all. There is too much emphasis on trials with ‘positive’ findings, and the attendant obsession with 
significant p-values, as opposed to effect estimates and confidence intervals. The wealth of clinical 
information provided by a well-conducted clinical trial is frequently ignored. This reflects the 
frustration when, often following years of anticipation, a new treatment simply does not deliver on 
the initial promise. Similarly, we often struggle to accept that treatments developed from first 
principles of physiology may sometimes prove to be ineffective. Perhaps our expectations are 
sometimes unrealistic? Whether the general public, the media or clinician, we all love to hear exciting 
news about an innovative treatment which will revolutionise treatment of disease. The purpose of 
pragmatic trials, however, is not to extend knowledge into exciting and novel areas but to enhance 
the acuity of clinical evidence on an existing question. A well designed clinical trial on an important 
question can never be ‘negative’. These findings ensure patients are no longer exposed to the risks 
of an ineffective or even harmful treatment, and scarce healthcare resources can be reinvested 
elsewhere. This concept, sometimes described as de-adoption and exnovation, has an increasingly 
important place in the delivery of modern healthcare and must not be dismissed. [12,17] 
 
How should we perform randomised trials? 
There are numerous challenges to designing and completing a pragmatic trial. The pressure to 
achieve academic success or work within finite research funding may force investigators to make 
compromises. Poor choices in terms of inclusion criteria, sample size and clinical outcome measures 
are commonplace. In many cases, randomised trials fail because researchers fail to either pose a 
relevant question or to design a trial which is appropriate to answer it. It is crucial that we don’t 
progress to pragmatic trials until we have a sound biological basis for our treatment strategy in terms 
of dose, timing and patient population. This often means taking several years to conduct smaller 
explanatory and feasibility trials to provide the information needed to design the optimal large 
pragmatic trial. The reluctance to thoroughly test biological plausibility, refine the design and study 
processes of large trials, has been the downfall of many investigators. Futility of the trial might be 
associated with futility of the treatment, but it can also arise due to a poorly designed trial, 
inadequate delivery of the study treatment or a lack of eligible patients. Consequently, many 
promising treatments might be discounted simply because of badly designed trials. 
 
Another common problem with pragmatic trials is a failure to focus on outcomes which are 
important to patients. Historically, research in anaesthesia and surgery has focused on health status 
in the immediate (30-day) post-operative period.[18] The vast majority of patients who consent to 
surgery do not do so simply to be alive 30 days later. Rather, they hope for a return to a desired level 
of functional independence, or to enjoy a good quality of life for the longest time possible. Patients 
and the public have much to offer as research partners and their involvement is now rightly seen as 
a marker of research excellence.[19,20] Pragmatic trials must focus on a small number of clinical 
outcomes, which are realistically modifiable by the study treatment, and are of direct relevance to 
patients. This must also include reporting of safety outcomes which for many years were often 
ignored in our field. The financial impact of treatments must also be considered in the era where it 
is recognised that wasted resources may actually contribute to harm elsewhere in the healthcare 
system. The cost of enhanced perioperative care may be more than covered by the financial savings 
achieved when fewer patients develop complications. Hence, what is good for patient care may be 
good for the healthcare economy as well. High quality perioperative care has the potential to save 
money as well as lives.[21,22]  To this end, we believe that every major trial of a perioperative 
treatment should include a cost effectiveness analysis. 
 
Finally, when well conducted, pragmatic trials do produce new knowledge beneficial to patients, we 
must engage with widespread adoption and implementation at scale, to ensure that patients benefit 
as quickly as possible. The good pragmatic trial should include a plan for implementation, beginning 
with the dissemination of knowledge. Clinicians commonly dispute outcome data from studies, not 
because of limitations in trial design, but because the findings don’t fit their own priors, 
preconceptions and knowledge base. They place emphasis on certain harms but ignore others. Sadly, 
the anaesthetist’s understanding of physiology is often outdated and incorrect, frequently differing 
widely between clinicians. Sometimes the findings of high-quality research may challenge our 
beliefs.[23] We must learn to accept unexpected or even unwelcome findings of large trials which 
have been well designed and conducted. Instead of dismissing results we cannot explain, we must 
seek to understand why an intervention can benefit or harm patients. We must also be prepared to 
accept that some benefits or harms are simply not as important as we previously thought. 
 
Conclusions 
Patients expect us to use the best possible evidence to determine what their best possible treatment 
should be. With more than 300 million patients undergoing surgery worldwide each year, the need 
for high quality clinical trials in perioperative medicine has never been greater. Like all research 
methods, pragmatic clinical trials have limitations. Many of these can be avoided through better, 
more thoughtful trial design. Pragmatic trials cannot provide answers to every important clinical 
question however, it is unwise to dismiss them or the knowledge they provide.  
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